CTRI/2024/04/065259尚未招募未知
Assessment of Renoprotective effect of cilnidipine and amlodipine along with telmisartan in patients with type-2 diabetes and hypertension – a Prospective observational study. - NI
Sri Ramaswamy Memorial0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •male and female patients aged 18 years and above diagnosed with hypertension and diabetes mellitus patient with RAS inhibitor such as telmisartan use for more than six months
排除标准
- •patients with severe hypertension greater than 180/95 and significant renal impairment CKD stage 2to5 were not included in the study malignant hypertension heart failure with in six months of cardiovascular events severe diabetes HbA1c above 9 were not included in the study pregnant and lactating women if the patient have low blood pressure or hypotensive below 110 they will be excluded if the proteinuria level also decreases the patient is excluded
研究者
相似试验
已完成
4 期
Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic NephropathyDiabetic NephropathyNCT00311870Steno Diabetes Center Copenhagen52
进行中（未招募）
1 期
This study will assess the effects of dapagliflozin (a drug that is used in patients with Type 2 Diabetes) on lowering the level of urine protein in patients with non-diabetic kidney disease.Chronic kidney diseaseEUCTR2017-001090-16-NLniversity Medical Center Groningen53
招募中
不适用
To Compare the renoprotective effect of sitagliptin and vildagliptin for patient with type 2 diabetic nephropathyDiabetic nephropathyJPRN-UMIN000011678Machida Municipal Hospital60
已完成
不适用
A comparative study of renoprotective effect of tolvaptan as an alternative treatment for increasing loop diuretics in patients with chronic kidney disease complicated with chronic heart failurechronic heart failure, chronic kidney diseaseJPRN-UMIN000036119Kawashima hospital40
已完成
3 期
A study to assess the renoprotective effects of the SGLT2 inhibitor Dapagliflozin in non-diabetic patients with proteinuria: a randomized double blind 6-week cross-over trialChronic kidney diseaseNL-OMON47662niversitair Medisch Centrum Groningen20